Karyopharm Therapeutics Inc.
KPTIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 31, 2026 | H.C. Wainwright | Robert Burns | $3.00(-57%) | $7.01 | TheFly |
| Jul 31, 2026 | Robert W. Baird | $3.00(-57%) | $7.01 | TheFly | |
| Jul 21, 2026 | RBC Capital | Brian Abrahams | $16.00(+97%) | $8.11 | StreetInsider |
| May 6, 2026 | H.C. Wainwright | $13.00(+38%) | $9.41 | TheFly | |
| Apr 27, 2026 | Piper Sandler | $16.00(+85%) | $8.66 | TheFly | |
| Mar 9, 2026 | UBS | $28.00(+230%) | $8.49 | TheFly | |
| Dec 17, 2025 | Goldman Sachs | $12.00(+90%) | $6.33 | StreetInsider | |
| Dec 17, 2025 | Piper Sandler | $12.00(+90%) | $6.33 | StreetInsider | |
| Nov 4, 2025 | RBC Capital | Brian Abrahams | $19.00(+239%) | $5.60 | TheFly |
| Oct 13, 2025 | H.C. Wainwright | Robert Burns | $15.00(+173%) | $5.50 | TheFly |
| Oct 9, 2025 | Robert W. Baird | $21.00(+256%) | $5.90 | TheFly | |
| Oct 8, 2025 | Leerink Partners | $6.00(+2%) | $5.91 | TheFly | |
| Jun 10, 2024 | RBC Capital | Brian Abrahams | $3.00(+215%) | $0.95 | StreetInsider |
| Jan 10, 2023 | Leerink Partners | $5.00(+76%) | $2.84 | Benzinga | |
| Aug 23, 2022 | Robert W. Baird | Collen Kusy | $14.00(+152%) | $5.56 | Pulse 2.0 |
| Mar 10, 2022 | RBC Capital | Brian Abrahams | $8.00(+23%) | $6.49 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Rodman & Renshaw | downgrade | Buy →Neutral | Nov 2, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jul 31, 2026 |
| Piper Sandler | maintain | Overweight | Jul 31, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2026 |
| Piper Sandler | maintain | Overweight | Apr 27, 2026 |
| Piper Sandler | maintain | Overweight | Mar 30, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2026 |
| Baird | maintain | Outperform | Mar 25, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 18, 2026 |
| RBC Capital | maintain | Outperform | Nov 4, 2025 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Oct 13, 2025 |
| Baird | maintain | Outperform | Oct 9, 2025 |
| Piper Sandler | maintain | Overweight | Oct 9, 2025 |
| Baird | maintain | Outperform | Aug 12, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jul 16, 2025 |
| RBC Capital | maintain | Outperform | May 13, 2025 |
| Baird | maintain | Outperform | May 13, 2025 |
| Barclays | maintain | Overweight | May 13, 2025 |
| Baird | maintain | Outperform | Mar 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 20, 2025 |
| RBC Capital | maintain | Outperform | Feb 20, 2025 |
| RBC Capital | maintain | Outperform | Feb 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2024 |
Earnings History
Next report: Feb 10, 2027 · EPS est. $-0.74| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-2.32 | $-1.37 | $33.4M | $32.2M |
| May 14, 2026 | $-1.24 | $-1.45 | $35.1M | $31.4M |
| Feb 12, 2026 | $-5.68 | $-2.26 | $34.1M | $35.1M |
| Nov 3, 2025 | $-3.82 | $-3.47 | $44.0M | $42.1M |
| Aug 11, 2025 | $-4.32 | $-3.80 | $37.9M | $38.0M |
| May 12, 2025 | $-2.77 | $-4.21 | $30.0M | $35.1M |
| Feb 19, 2025 | $-3.60 | $-0.25 | $30.5M | $35.7M |
| Nov 5, 2024 | $-3.90 | $-3.94 | $38.8M | $37.9M |
News
– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that abstracts from two of its clinical trials evaluating selinexor in patients with myelofibrosis were selected for oral presentations …
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – – Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize Business Value for all Stakeholders – – The Company Receives a Commitment of $55 Million in Additional Financing and Ongoing Operations Are Expected to be Uninterrupted During Sale Process – NEWTON, Mass., Nov. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the …
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee.
Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) and Alpha Cognition (NASDAQ: ACOG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations. Analyst Ratings This is a breakdown of
NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees.
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIOÂ (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to a loss of $4.32 per share a year ago.
– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3 SENTRY Results Presented at ASCO and EHA and Published in the Journal of Clinical Oncology; Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis – – Total Revenue was $33.4 Million, and U.S. XPOVIO® (selinexor) Net Product Revenue was $30.8 …
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.